Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature.

Autor:	Thomas CE; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Georgeson P; Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.; University of Melbourne Centre for Cancer Research, The University of Melbourne, Parkville, Australia., Qu C; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Steinfelder RS; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Buchanan DD; Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.; University of Melbourne Centre for Cancer Research, The University of Melbourne, Parkville, Australia.; Genomic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia., Song M; Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Harrison TA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Um CY; Department of Population Science, American Cancer Society, Atlanta, Georgia., Hullar MA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Jenkins MA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia., Van Guelpen B; Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden., Lynch BM; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia., Melaku YA; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.; FHMRI Sleep, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Huyghe JR; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Aglago EK; Department of Epidemiology and Biostatistics, Imperial College London, School of Public Health, London, UK., Berndt SI; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Boardman LA; Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota., Campbell PT; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York., Cao Y; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.; Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri.; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Chan AT; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Drew DA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Figueiredo JC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., French AJ; Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Giannakis M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Goode EL; Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota., Gruber SB; Department of Medical Oncology and Therapeutics Research and Center for Precision Medicine, City of Hope National Medical Center, Duarte, California., Gsur A; Center for Cancer Research, Medical University of Vienna, Vienna, Austria., Gunter MJ; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London, UK., Hoffmeister M; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hsu L; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle, Washington., Huang WY; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Moreno V; Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.; ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain., Murphy N; Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France., Newcomb PA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Epidemiology, University of Washington, Seattle, Washington., Newton CC; Department of Population Science, American Cancer Society, Atlanta, Georgia., Nowak JA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts., Obón-Santacana M; Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.; ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Ogino S; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sun W; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington., Toland AE; Departments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Trinh QM; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Ugai T; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Zaidi SH; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Peters U; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Epidemiology, University of Washington, Seattle, Washington., Phipps AI; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Epidemiology, University of Washington, Seattle, Washington.
Jazyk:	angličtina
Zdroj:	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2024 Apr 03; Vol. 33 (4), pp. 534-546.
DOI:	10.1158/1055-9965.EPI-23-0600
Abstrakt:	Background: The genotoxin colibactin causes a tumor single-base substitution (SBS) mutational signature, SBS88. It is unknown whether epidemiologic factors' association with colorectal cancer risk and survival differs by SBS88. Methods: Within the Genetic Epidemiology of Colorectal Cancer Consortium and Colon Cancer Family Registry, we measured SBS88 in 4,308 microsatellite stable/microsatellite instability low tumors. Associations of epidemiologic factors with colorectal cancer risk by SBS88 were assessed using multinomial regression (N = 4,308 cases, 14,192 controls; cohort-only cases N = 1,911), and with colorectal cancer-specific survival using Cox proportional hazards regression (N = 3,465 cases). Results: 392 (9%) tumors were SBS88 positive. Among all cases, the highest quartile of fruit intake was associated with lower risk of SBS88-positive colorectal cancer than SBS88-negative colorectal cancer [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.37-0.76; OR = 0.75, 95% CI 0.66-0.85, respectively, Pheterogeneity = 0.047]. Among cohort studies, associations of body mass index (BMI), alcohol, and fruit intake with colorectal cancer risk differed by SBS88. BMI ≥30 kg/m2 was associated with worse colorectal cancer-specific survival among those SBS88-positive [hazard ratio (HR) = 3.40, 95% CI 1.47-7.84], but not among those SBS88-negative (HR = 0.97, 95% CI 0.78-1.21, Pheterogeneity = 0.066). Conclusions: Most epidemiologic factors did not differ by SBS88 for colorectal cancer risk or survival. Higher BMI may be associated with worse colorectal cancer-specific survival among those SBS88-positive; however, validation is needed in samples with whole-genome or whole-exome sequencing available. Impact: This study highlights the importance of identification of tumor phenotypes related to colorectal cancer and understanding potential heterogeneity for risk and survival. (©2024 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu